Chase Sun(SZ:300026) Xin Lang Cai Jing·2025-10-17 01:30Core Viewpoint - Hongri Pharmaceutical experienced a slight increase in stock price and trading volume, with notable financing activities indicating a mixed sentiment among investors [1][2]. Financing Activities - On October 16, Hongri Pharmaceutical recorded a financing buy-in amount of 21.19 million yuan, with a net financing buy of 3.67 million yuan after repayments [1]. - The total financing and securities balance reached 631 million yuan, accounting for 5.54% of the circulating market value, which is below the 10% percentile level over the past year, indicating a low financing level [1]. - The company had a securities lending balance of 1.14 million yuan, with a lending volume of 30,140 shares, which is above the 60% percentile level over the past year, suggesting a higher level of short selling [1]. Financial Performance - For the first half of 2025, Hongri Pharmaceutical reported a revenue of 2.795 billion yuan, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 78.63 million yuan, down 46.95% year-on-year [2]. - Cumulatively, the company has distributed 1.116 billion yuan in dividends since its A-share listing, with 270 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 2.01% to 100,800, while the average circulating shares per person increased by 1.98% to 27,160 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited increased its holdings by 5.77 million shares to 26.07 million shares, while Southern CSI 1000 ETF increased its holdings by 3.71 million shares to 19.46 million shares [3].